The Melanocortin System
The melanocortin system comprises a family of peptide hormones (melanocortins) and their receptors (MC1R through MC5R). This system regulates diverse physiological processes including pigmentation, inflammation, energy homeostasis, and sexual function. PT 141 primarily targets the MC3R and MC4R subtypes.
From Melanotan to PT 141
PT 141's development traces back to Melanotan II, a synthetic melanocortin analogue originally developed for tanning research. During clinical trials, researchers observed unexpected effects on sexual function, leading to the development of PT 141 (Bremelanotide) as a focused compound for this indication.
Mechanism of Action
Unlike PDE5 inhibitors that act on vascular smooth muscle, PT 141 works through the central nervous system. It activates MC4R receptors in the hypothalamus, influencing neural pathways involved in sexual arousal and desire. This central mechanism of action distinguishes it from all other compounds in this therapeutic area.
FDA Approval
PT 141 (marketed as Vyleesi) received FDA approval in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This made it the first melanocortin based therapeutic to receive regulatory approval for this indication.
Research Applications
Beyond its approved indication, PT 141 is studied in several research contexts including melanocortin receptor pharmacology, central nervous system sexual function pathways, energy homeostasis and appetite regulation, and inflammatory modulation via melanocortin receptors.
Conclusion
PT 141 represents a unique compound in peptide research, offering a central nervous system based mechanism for studying sexual function and melanocortin receptor pharmacology. Its FDA approved status provides a strong foundation of safety and efficacy data for ongoing research.
All products are for research purposes only. Not for human consumption.